Accepting Cases

Gadolinium Lawsuit

Patients are suing the different makers of brands of gadolinium-based contrast agents (GBCAs) used in MRI and other radiographic imaging exams. Lawsuits claim that the manufacturers knew about the drugs’ dangers but failed to inform consumers. Plaintiffs in past lawsuits claimed GBCAs caused them to develop nephrogenic systemic fibrosis (NSF). Current lawsuits say the MRI contrast dyes can cause gadolinium deposition disease (GDD).

Suffered from gadolinium toxicity?

If you or a loved one suffered gadolinium toxicity after using a gadolinium-based contrast agent, you may be eligible for compensation.

Gadolinium Vial
Gadolinium Lawsuit Facts
  1. Injuries Gadolinium toxicity; Gadolinium Deposition Disease (GDD); Nephrogenic Systemic Fibrosis (NSF)
  2. Manufacturers Bayer (Magnevist); GE Healthcare (Omniscan); Guerbet (OptiMARK); Bracco Diagnostics Inc. (MultiHance)
  3. Top Verdict or Settlement $5 million nephrogenic systemic fibrosis (NSF) verdict against GE Healthcare in 2013
Fact-Checked

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Related Pages

**Update: Drugwatch’s legal partners are currently accepting lawsuits for patients who suffer from gadolinium toxicity and/or gadolinium deposition disease (GDD). These cases are still in the beginning stages of litigation.

Gadolinium lawsuits say patients can experience gadolinium toxicity after having an MRI scan with a linear gadolinium-based contrast agent (GBCA). Gadolinium is a metal used in MRI contrast dyes to help produce better images for doctors.

Patients who experienced symptoms of gadolinium toxicity after having an MRI — and who had no known kidney issues before the scan — may be eligible to file a lawsuit.

In 2018, the U.S. Food and Drug Administration approved updated prescribing information to include warnings about gadolinium retention. Conditions caused by gadolinium retention are progressive and can be life-threatening.

Research and adverse events reports to the FDA link GBCAs to gadolinium toxicity, gadolinium deposition disease (GDD) and nephrogenic systemic fibrosis (NSF). Studies link linear MRI contrast dyes to more problems than macrocytic contrast dyes.

Gadolinium lawsuits claim that manufacturers of gadolinium-based contrast agents used in MRI and other imaging exams knew about the contrast dye’s dangers but failed to warn the public.

Past gadolinium lawsuits involved nephrogenic systemic fibrosis in people with poor kidney function. Current lawsuits focus on people with normal kidney function who developed gadolinium deposition disease from linear contrast dyes.

Injuries in Gadolinium Deposition Disease Lawsuits

Illustration of kidneys.
Gadolinium lawsuits claim GDD occurred in people who had no known prior kidney issues.

People who filed MRI contrast lawsuits for gadolinium deposition disease claim GBCAs caused them to develop GDD. Plaintiffs had normal kidney function at the time they developed the disease.

Gadolinium deposition disease is progressive and has no known cure.

Symptoms of GDD mentioned in lawsuits include:
  • Persistent headaches
  • Weight loss
  • Kidney impairment
  • Body aches and stiffness
  • Bone and joint pain
  • Brain fog
  • Thickening of the skin that appear spongey or rubbery
  • Thick, painful ligaments and tendons
  • Cutting, burning pain in arms, legs and the torso

Allegations Against Manufacturers in MRI Contrast Lawsuits

GBCA manufacturers knew their products could cause toxicity but did not warn people or doctors about the potential serious side effects of gadolinium, according to lawsuits.

Lawsuits also claim that GBCA manufacturers had a duty to ensure their products were safe. But they did not properly test, design or manufacture their contrast agents.

Defendant companies showed “willful and conscious disregard of the rights and safety of others,” according to Munnuru vs. Guerbet LLC et al., a lawsuit filed in the Northern District of California.

Brands in Gadolinium Toxicity Lawsuits

Gadolinium lawyers are accepting cases for linear agents.

There are two basic types of GBCAs: linear and macrocyclic. These agents surround the gadolinium ions when injected into the body. This lowers toxicity levels.

Linear agents do not fully surround the gadolinium ions, and macrocyclic agents do, according to lawsuits. So, linear agents are more likely to cause gadolinium toxicity.

Linear Gadolinium-Based Contrast Agent Brands & Manufacturers
Brand Name Manufacturer
Magnevist Bayer
Omniscan GE Healthcare
Optimark Geurbet
Multihance Bracco

Filing a Gadolinium Toxicity Lawsuit

People can file gadolinium lawsuits on their own, but it can be expensive and complicated. Gadolinium attorneys can help people and their families properly file cases.

The law firm pays for all the costs upfront and doesn’t collect fees unless lawyers obtain a verdict or settlement. Gadolinium lawsuit case evaluations are free.

Experiencing symptoms of gadolinium toxicity? Get a Free Case Review

How Long Do I Have to File a Gadolinium Lawsuit?

The time limits to file a gadolinium lawsuit are called statues of limitations. The statute of limitations can be different depending on the facts of the case and the state where the case is filed.

Most states have a time limit of three years. If a person died as a result of gadolinium deposition disease or other injury, the time limit is two years.

An experienced gadolinium lawyer will be able to explain the time limit for a specific claim.

Are There Gadolinium Class Action Lawsuits?

There are currently no class action lawsuits for gadolinium deposition disease or gadolinium toxicity. So far, plaintiffs continue to file individual lawsuits.

Gadolinium Lawsuit Settlements & Verdicts

Because gadolinium deposition disease lawsuits are so new, there are not yet any settlements or verdicts.

But, in 2013, a jury ordered GE Healthcare to pay $5 million in a lawsuit that claimed an Ohio man, Paul Decker, developed nephrogenic systemic fibrosis (NSF) after being injected with the gadolinium-containing product Omniscan.

The case was the first to go to trial in a multidistrict litigation (MDL) in Cleveland, Ohio, involving thousands of gadolinium nephrogenic systemic fibrosis lawsuits. Most of the other cases in the MDL were settled.

Please seek the advice of a medical professional before making health care decisions.

Related Pages

Did you find Drugwatch helpful?

3 Cited Research Articles

  1. Munnuru v. Guerbet, LLC et al. (2018, January 26). United States District Court Northern District of California. Complaint for Damages. Case No. 4:18-cv-00571-SBA. Retrieved from https://jc6kx1c9izw3wansr3nmip8k-wpengine.netdna-ssl.com/wp-content/uploads/2018-01-26-Munnuru-Complaint.pdf
  2. Gever, J. (2011, January 25). GE Settles Omniscan Lawsuit. Medpage Today. Retrieved from https://www.medpagetoday.com/radiology/diagnosticradiology/24521
  3. U.S. Food and Drug Administration. (2018, May 16). FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. Retrieved from https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm
View All Sources
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(888) 610-4717

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.